Skip to main content
. Author manuscript; available in PMC: 2016 Oct 26.
Published in final edited form as: Vaccine. 2015 Sep 21;33(43):5845–5853. doi: 10.1016/j.vaccine.2015.08.086

Figure 3. MGC-CRX-601 formulations prepared in 10 mM HEPES or HEPES-Saline.

Figure 3

Particle size (diameter)/polydispersity (PDI) (A) and zeta-potential (ζ-potential) (B) values as a function of increasing MGC concentration for formulations prepared in 10 mM HEPES (■) vs. 10 mM HEPES-Saline (■) indicating lower polydispersity for formulations prepared in HEPES-Saline. All formulations contained CRX-601 at 1 mg/mL. Particle size is graphically represented by bars while PDI is shown as dot plot. Representative size distribution profiles obtained by dynamic light scattering (DLS) for MGC-CRX-601 complexes at 2 mg/mL MGC prepared in 10 mM HEPES (C) indicating multimodal size distribution vs. those obtained in 10 mM HEPES-Saline (D) indicating a largely unimodal distribution. The data in (A) and (B) represents mean ± standard deviation of three independent experiments. Data were analyzed by t-test (two-tails, equal variance). *, p <0.05, **, p <0.005